Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Conditions
Brief summary
In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
Detailed description
This is a prospective observation study to generate patient-derived organoids from patients' samples to assess treatment response and to correlate with patients' treatment outcomes and to collect preliminary data on the ability of PDOs to predict patients' treatment response and whether their radiosensitivity and chemosensitivity can be correlated with their survival outcome.
Interventions
None listed
Sponsors
Guy's and St Thomas' NHS Foundation Trust
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Patients with head and neck squamous cell carcinoma (including oral cavity, oropharynx, paranasal sinuses, hypopharynx or larynx) undergoing curative treatment (primary surgery or radiotherapy) or presenting with recurrent or metastatic cancers * Age \> 18 years old
Exclusion criteria
* Patients unable to give informed consent e.g. mental disability or vulnerable adults
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Successful Organoids | 1 Year | To assess the percentage of successful generated organoids from tissues in head and neck cancer patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Sensitivity | 1 Year | To assess the sensitivity of radiotherapy, platinum (cisplatin and/or carboplatin) chemotherapy or cetuximab or their combination in PDOs |
| Treatment Outcome | 1 Year | To correlate the treatment sensitivities of PDOs with the treatment outcome of patients |
Other
| Measure | Time frame | Description |
|---|---|---|
| Treatment Sensitivities | 1 Year | To correlate the treatment sensitivities of PDOs with the detection rates of plasma ctDNA (all cohorts) |
| Translational Research | 1 Year | Collection of archival tissues, blood samples (for ctDNA and PBMC), saliva (for ctDNA), urine or stool samples for other translational research |
| Patients Features | 1 Year | To assess and correlate the histopathological, genomic and transcriptomic features of patients' samples with PDOs |
| PDOs Sensitivities | 1 Year | To assess the sensitivities of PDOs to various targeted therapies based on their genomic profiles |
Countries
United Kingdom
Contacts
Primary ContactAnthony Kong
Backup ContactIfigenia Vasiliadou
Outcome results
None listed